Function
Locations
Couples oxidation of glyceraldehyde-3-phosphate to formation of the high-energy acyl-phosphate 1,3-bisphosphoglycerate and reduction of NAD+ to NADH (reviewed previously; also a well-known moonlighting protein).
The payoff (energy-yielding) phase of glycolysis is the second half of the cytosolic pathway, converting each glyceraldehyde-3-phosphate produced in the investment phase into pyruvate while generating ATP and NADH. Five steps: glyceraldehyde-3-phosphate dehydrogenase (GAPDH) oxidises and phosphorylates glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate, reducing NAD+ to NADH; phosphoglycerate kinase (PGK1) transfers a phosphate from 1,3-bisphosphoglycerate to ADP, forming 3-phosphoglycerate and the first ATP (substrate-level phosphorylation); phosphoglycerate mutase (muscle PGAM2) isomerises 3-phosphoglycerate to 2-phosphoglycerate; enolase (muscle ENO3) dehydrates 2-phosphoglycerate to phosphoenolpyruvate; and pyruvate kinase (liver/RBC PKLR, or muscle/other PKM) transfers the phosphate of phosphoenolpyruvate to ADP, forming pyruvate and the second ATP. Per glucose (two trioses) the payoff phase yields 4 ATP and 2 NADH, for a net glycolytic gain of 2 ATP + 2 NADH + 2 pyruvate. Because mature erythrocytes rely entirely on glycolytic ATP, defects here characteristically cause hereditary nonspherocytic hemolytic anemia, often combined with tissue-specific features: PGK1 deficiency (X-linked hemolytic anemia + myopathy + CNS disease); PGAM2 deficiency = glycogen storage disease type X (muscle); ENO3 deficiency = GSD type XIII (muscle); and PKLR deficiency = pyruvate kinase deficiency, the commonest glycolytic cause of hemolytic anemia.
All recommended fields populated.
✗ none found
No MODULE:glycolysis_payoff_phase deep-research report alongside the module YAML.
✓ every leaf node grounds to a representative protein.
✓ every declared conforms_to bundle matches its template motif.
6 complete review(s) · 2 with deep research · 0 missing review · 4 reviewed but lacking deep research
| Gene | Review | Complete | Deep research |
|---|---|---|---|
| ENO3 P13929 | ✓ | ✓ | ✗ |
| GAPDH P04406 | ✓ | ✓ | ✓ |
| PGAM2 P15259 | ✓ | ✓ | ✗ |
| PGK1 P00558 | ✓ | ✓ | ✗ |
| PKLR P30613 | ✓ | ✓ | ✗ |
| PKM P14618 | ✓ | ✓ | ✓ |
Five-step payoff phase of glycolysis grounded to the human enzymes GAPDH (UniProtKB:P04406, GO:0004365), phosphoglycerate kinase PGK1 (P00558, GO:0004618), phosphoglycerate mutase PGAM2 (P15259, GO:0004619), beta-enolase ENO3 (P13929, GO:0004634) and pyruvate kinase PKLR (P30613) / PKM (P14618) (GO:0004743). GO molecular-function terms were taken from the human GOA records; Reactome reaction ids and titles were verified against the local reactome cache. Each step uses a PANTHER family selector generic over the tissue isozymes and orthologs (PGAM node covers PGAM1/PGAM2/BPGM; enolase node ENO1/ENO2/ENO3; pyruvate-kinase node PKLR + PKM). GAPDH and PKM were reviewed previously (already on main) and are cross-linked via file: evidence; PGK1/PGAM2/ENO3/PKLR are the reviews new in this batch. Upstream, the two glyceraldehyde-3-phosphate molecules come from the glycolysis investment phase (hexokinase -> GPI -> PFK -> aldolase -> TPI); downstream, pyruvate feeds the pyruvate-metabolism module (PDC/PC) and lactate fermentation (LDHA/LDHB, a separate module), while the reverse reactions (except the PFK/PK/hexokinase committed steps) serve gluconeogenesis. Moonlighting roles (GAPDH; PGK1 extracellular reductase; PKM2 nuclear/protein-kinase) are captured non-core in the individual gene reviews. Disorders: PGK1 (X-linked hemolytic anemia + myopathy + CNS); PGAM2 (GSD X); ENO3 (GSD XIII); PKLR (pyruvate kinase deficiency, hemolytic anemia).
Couples oxidation of glyceraldehyde-3-phosphate to formation of the high-energy acyl-phosphate 1,3-bisphosphoglycerate and reduction of NAD+ to NADH (reviewed previously; also a well-known moonlighting protein).
Generates the first ATP of glycolysis by substrate-level phosphorylation (reverse direction in gluconeogenesis). X-linked PGK1 deficiency causes hemolytic anemia with myopathy and CNS disease; PGK2 is testis-specific.
Interconverts 3- and 2-phosphoglycerate (dimer of the muscle PGAM2/M and brain PGAM1/B subunits; muscle = PGAM2 homodimer). PGAM2 deficiency = GSD type X (exercise intolerance, myoglobinuria).
Mg2+-dependent dehydration of 2-phosphoglycerate to phosphoenolpyruvate. Tissue isozymes ENO1 (alpha, ubiquitous), ENO2 (gamma, neuronal), ENO3 (beta, muscle); ENO3 deficiency = GSD type XIII.
Final, essentially irreversible glycolytic step generating the second ATP; homotetramer, Mg2+/K+-dependent, allosterically activated by fructose-1,6-bisphosphate. PKLR (liver/RBC) deficiency = pyruvate kinase deficiency (commonest glycolytic hemolytic anemia); PKM = muscle/other.